Clinical significance of HIV-1 coreceptor usage

Journal of Translational Medicine

Volumn 9, Issue SUPPL. 1, 2010, Pages

  Schuitemaker, Hanneke ^a,c   Van 't Wout, Angélique B ^a,c   Lusso, Paolo ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; LAMIVUDINE; RITONAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DISEASE COURSE; DRUG EFFICACY; EX VIVO STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; IN VIVO STUDY; INFECTION SENSITIVITY; MOLECULAR EVOLUTION; NONHUMAN; PATHOGENESIS; PHENOTYPIC VARIATION; PROTECTION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS IDENTIFICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 79251483142     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-S1-S5     Document Type: Review

References (174)

1. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815. 10.1126/science.270.5243.1811, 8525373.
2. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877. 10.1126/science.272.5263.872, 8629022.
3. Lusso P. HIV and the chemokine system: 10 years later. Embo J 2006, 25:447-456. 10.1038/sj.emboj.7600947, 1383531, 16437164.
4. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA. A new classification for HIV-1. Nature 1998, 391:240. 10.1038/34571, 9440686.
5. Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007, 81:7885-7893. 10.1128/JVI.00218-07, 1951291, 17507467.
6. Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. Aids 2008, 22:1425-1431. 10.1097/QAD.0b013e32830184ba, 18614865.
7. Yi Y, Isaacs SN, Williams DA, Frank I, Schols D, De Clercq E, Kolson DL, Collman RG. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. J Virol 1999, 73:7117-7125. 104231, 10438797.
8. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666. 10.1038/381661a0, 8649511.
9. Cecilia D, KewalRamani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, Zolla-Pazner S. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998, 72:6988-6996. 109918, 9696790.
10. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007, 51:566-575. 10.1128/AAC.00853-06, 1797738, 17116663.
11. Coakley E, Reeves JD, Huang W, Mangas-Ruiz M, Maurer I, Harskamp AM, Gupta S, Lie Y, Petropoulos CJ, Schuitemaker H, van 't Wout AB. Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. Antimicrob Agents Chemother 2009, 53:4686-4693. 10.1128/AAC.00229-09, 2772338, 19687240.
12. De Wolf F, Hogervorst E, Goudsmit J, Fenyo EM, Rubsamen-Waigmann H, Holmes H, Galvao-Castro B, Karita E, Wasi C, Sempala SD, et al. Syncytium-inducing and non- syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994, 10:1387-1400. 10.1089/aid.1994.10.1387, 7888192.
13. Zhang YJ, Dragic T, Cao Y, Kostrikis L, Kwon DS, Littman DR, KewalRamani VN, Moore JP. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol 1998, 72:9337-9344. 110357, 9765485.
14. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med 1997, 185:621-628. 10.1084/jem.185.4.621, 2196142, 9034141.
15. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997, 3:1259-1265. 10.1038/nm1197-1259, 9359702.
16. Abebe A, Demissie D, Goudsmit J, Brouwer M, Kuiken CL, Pollakis G, Schuitemaker H, Fontanet AL, Rinke de Wit TF. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Aids 1999, 13:1305-1311. 10.1097/00002030-199907300-00006, 10449282.
17. Batra M, Tien PC, Shafer RW, Contag CH, Katzenstein DA. HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe. AIDS Res Hum Retroviruses 2000, 16:973-979. 10.1089/08892220050058399, 10890359.
18. Bjorndal A, Sonnerborg A, Tscherning C, Albert J, Fenyo EM. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses 1999, 15:647-653. 10.1089/088922299310944, 10331443.
19. Peeters M, Vincent R, Perret JL, Lasky M, Patrel D, Liegeois F, Courgnaud V, Seng R, Matton T, Molinier S, Delaporte E. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:115-121.
20. Ping LH, Nelson JA, Hoffman IF, Schock J, Lamers SL, Goodman M, Vernazza P, Kazembe P, Maida M, Zimba D, et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol 1999, 73:6271-6281. 112705, 10400718.
21. Tscherning C, Alaeus A, Fredriksson R, Bjorndal A, Deng H, Littman DR, Fenyo EM, Albert J. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998, 241:181-188. 10.1006/viro.1997.8980, 9499793.
22. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV- 1 genetic subtypes and recombinants in 2004. Aids 2006, 20:W13-23. 10.1097/01.aids.0000247564.73009.bc, 17053344.
23. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003, 77:7682-7688. 10.1128/JVI.77.13.7682-7688.2003, 164829, 12805470.
24. Connell BJ, Michler K, Capovilla A, Venter WD, Stevens WS, Papathanasopoulos MA. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. Aids 2008, 22:896-899. 10.1097/QAD.0b013e3282f57f7a, 18427209.
25. Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire-Lugemwa J, Lule DB, Morgan D, Beddows S, Weber J, Whitworth JA. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007, 45:28-33. 10.1097/QAI.0b013e3180385aa0, 17310935.
26. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, Mandaliya K, Jaoko W, Overbaugh J. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007, 195:1177-1180. 10.1086/512682, 17357054.
27. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, Fawzi W, Hunter D. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006, 42:843-852. 10.1086/499952, 16477563.
28. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter A, Tatt ID, Geretti AM, Zuckerman M. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 13:4. 10.1186/1758-2652-13-4, 2827379, 20205896.
29. Yu XF, Wang Z, Beyrer C, Celentano DD, Khamboonruang C, Allen E, Nelson K. Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand. J Virol 1995, 69:4649-4655. 189267, 7609029.
30. Utaipat U, Duerr A, Rudolph DL, Yang C, Butera ST, Lupo D, Pisell T, Tangmunkongvorakul A, Kamtorn N, Nantachit N, et al. Coreceptor utilization of HIV type 1 subtype E viral isolates from Thai men with HIV type 1-infected and uninfected wives. AIDS Res Hum Retroviruses 2002, 18:1-11. 10.1089/088922202753394664, 11804551.
31. Tebit DM, Zekeng L, Kaptue L, Salminen M, Krausslich HG, Herchenroder O. Genotypic and phenotypic analysis of HIV type 1 primary isolates from western Cameroon. AIDS Res Hum Retroviruses 2002, 18:39-48. 10.1089/088922202753394709, 11804555.
32. Zhong P, S BU, Konings F, Urbanski M, Ma L, Zekeng L, Ewane L, Agyingi L, Agwara M, Saa, et al. Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity. AIDS Res Hum Retroviruses 2003, 19:1167-1178. 10.1089/088922203771881284, 14717120.
33. Esbjornsson J, Mansson F, Martinez-Arias W, Vincic E, Biague AJ, da Silva ZJ, Fenyo EM, Norrgren H, Medstrand P. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West Africa. Retrovirology 2010, 7:23. 10.1186/1742-4690-7-23, 2855529, 20307309.
34. Chesebro B, Nishio J, Perryman S, Cann A, O'Brien W, Chen IS, Wehrly K. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol 1991, 65:5782-5789. 250239, 1920616.
35. Groenink M, Fouchier RA, Broersen S, Baker CH, Koot M, van't Wout AB, Huisman HG, Miedema F, Tersmette M, Schuitemaker H. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993, 260:1513-1516. 10.1126/science.8502996, 8502996.
36. O'Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, Idler K, Zack JA, Chen IS. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 1990, 348:69-73. 10.1038/348069a0, 2172833.
37. Shioda T, Levy JA, Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1992, 89:9434-9438. 10.1073/pnas.89.20.9434, 50146, 1409653.
38. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium- inducing phenotype: analysis by single amino acid substitution. J Virol 1992, 66:6777-6780. 240176, 1404617.
39. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992, 66:3183-3187. 241084, 1560543.
40. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 1998, 72:2509-2515. 109554, 9499115.
41. Hoffman TL, Stephens EB, Narayan O, Doms RW. HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. Proc Natl Acad Sci U S A 1998, 95:11360-11365. 10.1073/pnas.95.19.11360, 21647, 9736741.
42. Ross TM, Cullen BR. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proc Natl Acad Sci U S A 1998, 95:7682-7686. 10.1073/pnas.95.13.7682, 22722, 9636210.
43. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659. 10.1038/31405, 9641677.
44. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000, 74:1961-1972. 10.1128/JVI.74.4.1961-1972.2000, 111674, 10644369.
45. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L, Olson W, Kwong PD, Sattentau QJ. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000, 74:1948-1960. 10.1128/JVI.74.4.1948-1960.2000, 111673, 10644368.
46. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280:1949-1953. 10.1126/science.280.5371.1949, 9632396.
47. Coetzer M, Cilliers T, Ping LH, Swanstrom R, Morris L. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 2006, 356:95-105. 10.1016/j.virol.2006.07.030, 16942785.
48. Jensen MA, Coetzer M, van 't Wout AB, Morris L, Mullins JI. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006, 80:4698-4704. 10.1128/JVI.80.10.4698-4704.2006, 1472078, 16641263.
49. Boisvert S, Marchand M, Laviolette F, Corbeil J. HIV-1 coreceptor usage prediction without multiple alignments: an application of string kernels. Retrovirology 2008, 5:110. 10.1186/1742-4690-5-110, 2637298, 19055831.
50. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003, 77:13376-13388. 10.1128/JVI.77.24.13376-13388.2003, 296044, 14645592.
51. Pillai S, Good B, Richman D, Corbeil J. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003, 19:145-149. 10.1089/088922203762688658, 12643277.
52. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001, 288:51-62. 10.1006/viro.2001.1087, 11543657.
53. Xu S, Huang X, Xu H, Zhang C. Improved prediction of coreceptor usage and phenotype of HIV-1 based on combined features of V3 loop sequence using random forest. J Microbiol 2007, 45:441-446.
54. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype- associated changes in the V3 loop. J Virol 2002, 76:3852-3864. 10.1128/JVI.76.8.3852-3864.2002, 136063, 11907225.
55. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, Buch J, Daumer M, Kaiser R, Lengauer T, Harrigan PR. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007, 12:1097-1106.
56. Sander O, Sing T, Sommer I, Low AJ, Cheung PK, Harrigan PR, Lengauer T, Domingues FS. Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol 2007, 3:e58. 10.1371/journal.pcbi.0030058, 1848001, 17397254.
57. Lamers SL, Salemi M, McGrath MS, Fogel GB. Prediction of R5, X4, and R5X4 HIV-1 coreceptor usage with evolved neural networks. IEEE/ACM Trans Comput Biol Bioinform 2008, 5:291-300. 10.1109/TCBB.2007.1074, 18451438.
58. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006, 80:4909-4920. 10.1128/JVI.80.10.4909-4920.2006, 1472081, 16641282.
59. Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, Whitcomb JM, Parkin N, Petropoulos CJ. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 2008, 82:5584-5593. 10.1128/JVI.02676-07, 2395220, 18353956.
60. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296:2354-2360. 10.1126/science.1070441, 12089434.
61. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, Jensen MA, Wynhoven B, Chan D, Glascock C, Harrigan PR. Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and "Deep" Sequencing to Plasma RNA and Proviral DNA. J Acquir Immune Defic Syndr 2010,
62. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359:1442-1455. 10.1056/NEJMoa0803154, 18832245.
63. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441. 10.1056/NEJMoa0803152, 18832244.
64. Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, et al. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009, 200:1724-1728. 10.1086/648090, 2783913, 19874179.
65. McGovern RA, Dong W, Zhong X, Mo T, Knapp D, Thielen A, Chapman D, Lewis M, James IT, Heera J, et al. Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trofile assay in predicting virologic response to maraviroc of treatment-naïve patients in the MERIT trial. In 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA 2010,
66. Swenson LC, Dong W, Mo T, Thielen A, Jensen MA, Chapman D, James IT, Heera J, Valdez H, Harrigan PR. Large-scale application of deep sequencing using 454 technology to HIV tropism screening. In 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA 2010,
67. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008, 105:7552-7557. 10.1073/pnas.0802203105, 2387184, 18490657.
68. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008, 82:3952-3970. 10.1128/JVI.02660-07, 2293010, 18256145.
69. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 2002, 18:567-576. 10.1089/088922202753747914, 12036486.
70. van 't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994, 94:2060-2067. 10.1172/JCI117560, 294642, 7962552.
71. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179-1181. 10.1126/science.8356453, 8356453.
72. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?. Nat Rev Microbiol 2006, 4:312-317. 10.1038/nrmicro1387, 16541138.
73. Harouse JM, Tan RC, Gettie A, Dailey P, Marx PA, Luciw PA, Cheng-Mayer C. Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology 1998, 248:95-107. 10.1006/viro.1998.9236, 9705259.
74. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. Aids 2001, 15:369-378. 10.1097/00002030-200102160-00010, 11273217.
75. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M, Johnson RP, Desrosiers RC, Lackner AA. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431. 10.1126/science.280.5362.427, 9545219.
76. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008, 9:301-309. 10.1038/ni1566, 18264102.
77. Cornelissen M, Mulder-Kampinga G, Veenstra J, Zorgdrager F, Kuiken C, Hartman S, Dekker J, van der Hoek L, Sol C, Coutinho R, et al. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium- inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol 1995, 69:1810-1818. 188790, 7853521.
78. Lathey JL, Pratt RD, Spector SA. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. J Infect Dis 1997, 175:231-232.
79. Frange P, Galimand J, Goujard C, Deveau C, Ghosn J, Rouzioux C, Meyer L, Chaix ML. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. JAntimicrob Chemother 2009, 64:135-141.
80. Frange P, Chaix ML, Raymond S, Galimand J, Deveau C, Meyer L, Goujard C, Rouzioux C, Izopet J. Low frequency of CXCR4-using viruses in patients at the time of primary HIV-1 non-B infection. J Clin Microbiol 2010,
81. Huang W, Toma J, Stawiski E, Fransen S, Wrin T, Parkin N, Whitcomb JM, Coakley E, Hecht FM, Deeks SG, et al. Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses 2009, 25:795-802. 10.1089/aid.2008.0252, 19678765.
82. Raymond S, Delobel P, Mavigner M, Cazabat M, Encinas S, Souyris C, Bruel P, Sandres-Saune K, Marchou B, Massip P, Izopet J. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. Aids 24:2305-2312.
83. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya GS, Treurnicht FK, Keele BF, Wood N, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009, 83:3556-3567. 10.1128/JVI.02132-08, 2663249, 19193811.
84. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, Sun C, Wang S, Learn GH, Morgan CJ, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010, 84:6241-6247. 10.1128/JVI.00077-10, 2876625, 20375173.
85. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O, Mulenga J, Keele BF, Shaw GM, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009, 5:e1000274. 10.1371/journal.ppat.1000274, 2621345, 19165325.
86. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Learn GH, Morgan CJ, et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog 2010, 6:e1000890. 10.1371/journal.ppat.1000890, 2869329, 20485520.
87. Masharsky AE, Dukhovlinova EN, Verevochkin SV, Toussova OV, Skochilov RV, Anderson JA, Hoffman I, Cohen MS, Swanstrom R, Kozlov AP. A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia. J Infect Dis 2010, 201:1697-1702. 10.1086/652702, 20423223.
88. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009, 206:1273-1289. 10.1084/jem.20090378, 2715054, 19487424.
89. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377. 10.1016/S0092-8674(00)80110-5, 8756719.
90. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862. 10.1126/science.273.5283.1856, 8791590.
91. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725. 10.1038/382722a0, 8751444.
92. Kupfer B, Kaiser R, Brackmann HH, Effenberger W, Rockstroh JK, Matz B, Schneweis KE. Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene. Aids 1999, 13:1025-1028. 10.1097/00002030-199906180-00004, 10397531.
93. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, Bakker M, Roos MT, Prins M, de Wolf F, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997, 127:882-890.
94. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001, 135:782-795.
95. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997, 3:338-340. 10.1038/nm0397-338, 9055864.
96. Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, Sheppard HW. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997, 3:1160-1162. 10.1038/nm1097-1160, 9334732.
97. Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, Metais P, Montagnier L, Virelizier JL, Arenzana-Seisdedos F, Beretta A. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998, 351:14-18. 10.1016/S0140-6736(97)09185-X, 9433423.
98. Sheppard HW, Celum C, Michael NL, O'Brien S, Dean M, Carrington M, Dondero D, Buchbinder SP. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 2002, 29:307-313.
99. Gray L, Churchill MJ, Keane N, Sterjovski J, Ellett AM, Purcell DF, Poumbourios P, Kol C, Wang B, Saksena NK, et al. Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol 2006, 80:3684-3691. 10.1128/JVI.80.7.3684-3691.2006, 1440368, 16537640.
100. Dalmau J, Puertas MC, Azuara M, Marino A, Frahm N, Mothe B, Izquierdo-Useros N, Buzon MJ, Paredes R, Matas L, et al. Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. Clin Infect Dis 2009, 48:229-238. 10.1086/595704, 2806184, 19093810.
101. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, Kim A, Chung C, Jean-Pierre P, Horowitz A, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005, 365:1031-1038.
102. Mohri H, Markowitz M. In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immune Defic Syndr 2008, 48:511-521. 10.1097/QAI.0b013e31817ecb31, 18645523.
103. Nielsen C, Pedersen C, Lundgren JD, Gerstoft J. Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. Aids 1993, 7:1035-1040. 10.1097/00002030-199308000-00002, 8104421.
104. Aasa-Chapman MM, Aubin K, Williams I, McKnight A. Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. Virology 2006, 351:489-496. 10.1016/j.virol.2006.04.002, 16712896.
105. Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, Hunter E, Derdeyn CA, Collman RG. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol 2009, 83:8208-8220. 10.1128/JVI.00296-09, 2715751, 19515785.
106. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.
107. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974.
108. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992, 66:1354-1360. 240857, 1738194.
109. Koot M, Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, Coutinho RA, Miedema F, Tersmette M. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. Aids 1992, 6:49-54. 10.1097/00002030-199201000-00006, 1543566.
110. Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck Schattenkerk JK, Reiss P, Tersmette M, Lange JM, Schuitemaker H. Conversion rate towards a syncytium- inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999, 179:254-258. 10.1086/314539, 9841850.
111. Ida S, Gatanaga H, Shioda T, Nagai Y, Kobayashi N, Shimada K, Kimura S, Iwamoto A, Oka S. HIV type 1 V3 variation dynamics in vivo: long-term persistence of non- syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS. AIDS Res Hum Retroviruses 1997, 13:1597-1609. 10.1089/aid.1997.13.1597, 9430252.
112. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999, 73:10489-10502. 113104, 10559367.
113. Koot M, van 't Wout AB, Kootstra NA, de Goede RE, Tersmette M, Schuitemaker H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996, 173:349-354.
114. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006, 194:238-246. 10.1086/504693, 16779731.
115. Huang W, Eshleman SH, Toma J, Stawiski E, Whitcomb JM, Jackson JB, Guay L, Musoke P, Parkin N, Petropoulos CJ. Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs. Aids 2009, 23:1903-1908. 10.1097/QAD.0b013e32832f1802, 2764460, 19593079.
116. Weiss SH, Goedert JJ, Gartner S, Popovic M, Waters D, Markham P, di Marzo Veronese F, Gail MH, Barkley WE, Gibbons J, et al. Risk of human immunodeficiency virus (HIV- 1) infection among laboratory workers. Science 1988, 239:68-71. 10.1126/science.3336776, 3336776.
117. Berkowitz RD, Beckerman KP, Schall TJ, McCune JM. CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. J Immunol 1998, 161:3702-3710.
118. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997, 94:1925-1930. 10.1073/pnas.94.5.1925, 20019, 9050881.
119. de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999, 163:4597-4603.
120. Blaak H, van 't Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium- inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci USA 2000, 97:1269-1274. 10.1073/pnas.97.3.1269, 15592, 10655520.
121. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006, 80:750-758. 10.1128/JVI.80.2.750-758.2006, 1346864, 16378977.
122. Bunnik EM, Quakkelaar ED, van Nuenen AC, Boeser-Nunnink B, Schuitemaker H. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol 2007, 81:525-531. 10.1128/JVI.01983-06, 1797458, 17079299.
123. Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 2005, 79:6957-6968. 10.1128/JVI.79.11.6957-6968.2005, 1112133, 15890935.
124. Harouse JM, Buckner C, Gettie A, Fuller R, Bohm R, Blanchard J, Cheng-Mayer C. CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci U S A 2003, 100:10977-10982. 10.1073/pnas.1933268100, 196912, 12963814.
125. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor- bound receptor for entry. J Virol 2007, 81:2359-2371. 10.1128/JVI.02006-06, 1865946, 17182681.
126. Scoggins RM, Taylor JR, Patrie J, van't Wout AB, Schuitemaker H, Camerini D. Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J Virol 2000, 74:3205-3216. 10.1128/JVI.74.7.3205-3216.2000, 111821, 10708437.
127. Karlsson I, Antonsson L, Shi Y, Oberg M, Karlsson A, Albert J, Olde B, Owman C, Jansson M, Fenyo EM. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004, 78:11807-11815. 10.1128/JVI.78.21.11807-11815.2004, 523262, 15479822.
128. Koning FA, Kwa D, Boeser-Nunnink B, Dekker J, Vingerhoed J, Hiemstra H, Schuitemaker H. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non- syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis 2003, 188:864-872. 10.1086/377105, 12964118.
129. Cavarelli M, Karlsson I, Zanchetta M, Antonsson L, Plebani A, Giaquinto C, Fenyo EM, De Rossi A, Scarlatti G. HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children. PLoS One 2008, 3:e3292. 10.1371/journal.pone.0003292, 2538568, 18820725.
130. Karlsson I, Antonsson L, Shi Y, Karlsson A, Albert J, Leitner T, Olde B, Owman C, Fenyo EM. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. Aids 2003, 17:2561-2569. 10.1097/00002030-200312050-00003, 14685050.
131. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 1999, 5:535-541. 10.1038/8414, 10229230.
132. van 't Wout AB, Blaak H, Ran LJ, Brouwer M, Kuiken C, Schuitemaker H. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. J Virol 1998, 72:5099-5107. 110075, 9573281.
133. Kuiken CL, de Jong JJ, Baan E, Keulen W, Tersmette M, Goudsmit J. Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 1992, 66:5704. 293507, 1501303.
134. Pastore C, Ramos A, Mosier DE. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 2004, 78:7565-7574. 10.1128/JVI.78.14.7565-7574.2004, 434079, 15220431.
135. Koning FA, Koevoets C, van der Vorst TJ, Schuitemaker H. Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors. Antivir Ther 2005, 10:231-237.
136. Repits J, Oberg M, Esbjornsson J, Medstrand P, Karlsson A, Albert J, Fenyo EM, Jansson M. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol 2005, 86:2859-2869. 10.1099/vir.0.81111-0, 16186242.
137. Stalmeijer EH, Van Rij RP, Boeser-Nunnink B, Visser JA, Naarding MA, Schols D, Schuitemaker H. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J Virol 2004, 78:2722-2728. 10.1128/JVI.78.6.2722-2728.2004, 353738, 14990692.
138. Asjo B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyo EM. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986, 2:660-662.
139. Connor RI, Mohri H, Cao Y, Ho DD. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993, 67:1772-1777. 240220, 8095306.
140. Ostrowski MA, Chun TW, Justement SJ, Motola I, Spinelli MA, Adelsberger J, Ehler LA, Mizell SB, Hallahan CW, Fauci AS. Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol 1999, 73:6430-6435. 112723, 10400736.
141. van Rij RP, Blaak H, Visser JA, Brouwer M, Rientsma R, Broersen S, de Roda Husman AM, Schuitemaker H. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J Clin Invest 2000, 106:1039-1052. 10.1172/JCI7953, 314337, 11032864.
142. Mild M, Esbjornsson J, Fenyo EM, Medstrand P. Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch. J Virol 2007, 81:3369-3376. 10.1128/JVI.01295-06, 1866041, 17251288.
143. van Rij RP, Worobey M, Visser JA, Schuitemaker H. Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination. Virology 2003, 314:451-459. 10.1016/S0042-6822(03)00454-9, 14517097.
144. Verhofstede C, Vandekerckhove L, Eygen VV, Demecheleer E, Vandenbroucke I, Winters B, Plum J, Vogelaers D, Stuyver L. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009, 50:126-136. 10.1097/QAI.0b013e31819118fa, 19131897.
145. Edo-Matas D, van Gils MJ, Bowles EJ, Navis M, Rachinger A, Boeser-Nunnink B, Stewart-Jones GB, Kootstra NA, van 't Wout AB, Schuitemaker H. Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 2010, 405:492-504. 10.1016/j.virol.2010.06.029, 20638697.
146. Seclen E, Del Mar Gonzalez M, De Mendoza C, Soriano V, Poveda E. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother 2010, 65:1493-1496. 10.1093/jac/dkq156, 20488982.
147. Abecasis AB, Vandamme AM, Lemey P. Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution. J Virol 2009, 83:12917-12924. 10.1128/JVI.01022-09, 2786833, 19793809.
148. Gray RR, Tatem AJ, Lamers S, Hou W, Laeyendecker O, Serwadda D, Sewankambo N, Gray RH, Wawer M, Quinn TC, et al. Spatial phylodynamics of HIV-1 epidemic emergence in east Africa. Aids 2009, 23:F9-F17. 10.1097/QAD.0b013e32832faf61, 2742553, 19644346.
149. Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M, Muyembe JJ, Kabongo JM, Kalengayi RM, Van Marck E, et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008, 455:661-664. 10.1038/nature07390, 18833279.
150. Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. The emergence of HIV/AIDS in the Americas and beyond. Proc Natl Acad Sci U S A 2007, 104:18566-18570. 10.1073/pnas.0705329104, 2141817, 17978186.
151. Koot M, Schellekens PT, Mulder JW, Lange JM, Roos MT, Coutinho RA, Tersmette M, Miedema F. Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J Infect Dis 1993, 168:733-736.
152. Karlsson A, Parsmyr K, Aperia K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. J Infect Dis 1994, 170:1367-1375.
153. van 't Wout AB, de Jong MD, Kootstra NA, Veenstra J, Lange JM, Boucher CA, Schuitemaker H. Changes in cellular virus load and zidovudine resistance of syncytium- inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. J Infect Dis 1996, 174:845-849.
154. van 't Wout AB, Ran LJ, de Jong MD, Bakker M, van Leeuwen R, Notermans DW, Loeliger AE, de Wolf F, Danner SA, Reiss P, et al. Selective inhibition of syncytium- inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J Clin Invest 1997, 100:2325-2332. 10.1172/JCI119771, 508429, 9410911.
155. van 't Wout AB, Ran LJ, Nijhuis M, Tijnagel JM, de Groot T, van Leeuwen R, Boucher CA, Schuitemaker H, Schuurman R. Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo. Aids 1998, 12:1169-1176. 10.1097/00002030-199810000-00009, 9677166.
156. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JS, Harrigan PR. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005, 192:466-474. 10.1086/431519, 15995960.
157. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005, 191:866-872. 10.1086/428096, 15717260.
158. Poveda E, Briz V, de Mendoza C, Benito JM, Corral A, Zahonero N, Lozano S, Gonzalez-Lahoz J, Soriano V. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 2007, 79:1040-1046. 10.1002/jmv.20900, 17596837.
159. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 2005, 18:9-15. 10.1097/00001432-200502000-00003, 15647694.
160. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006, 194:926-930. 10.1086/507312, 16960780.
161. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, et al. HIV type 1 chemokine coreceptor use among antiretroviral- experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007, 44:591-595. 10.1086/511035, 17243065.
162. Briz V, Poveda E, del Mar Gonzalez M, Martin-Carbonero L, Gonzalez-Gonzalez R, Soriano V. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. J Antimicrob Chemother 2008, 61:405-410. 10.1093/jac/dkm469, 18063598.
163. Equils O, Garratty E, Wei LS, Plaeger S, Tapia M, Deville J, Krogstad P, Sim MS, Nielsen K, Bryson YJ. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1- infected children responding to highly active antiretroviral therapy. J Infect Dis 2000, 182:751-757. 10.1086/315758, 10950768.
164. Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, Meyer WA, Sacks HS, Mathur-Wagh U, Brunner C, Burger H. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001, 107:431-438. 10.1172/JCI11526, 199259, 11181642.
165. Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, Clavel F, Mammano F. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. Aids 2003, 17:809-814. 10.1097/00002030-200304110-00005, 12660527.
166. Galan I, Jimenez JL, Gonzalez-Rivera M, De Jose MI, Navarro ML, Ramos JT, Mellado MJ, Gurbindo MD, Bellon JM, Resino S, et al. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. Aids 2004, 18:247-255. 10.1097/00002030-200401230-00014, 15075542.
167. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, Massip P, Izopet J. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005, 38:382-392. 10.1097/01.qai.0000152835.17747.47, 15764954.
168. Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, Ladisa N, Tartaglia A, Lagioia A, Angarano G. Co-receptor switch during HAART is independent of virological success. J Med Virol 2009, 81:2036-2044. 10.1002/jmv.21598, 19856465.
169. Lehmann C, Daumer M, Boussaad I, Sing T, Beerenwinkel N, Lengauer T, Schmeisser N, Wyen C, Fatkenheuer G, Kaiser R. Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol 2006, 37:300-304. 10.1016/j.jcv.2006.08.008, 17005445.
170. Soulie C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. Aids 2007, 21:2243-2245. 10.1097/QAD.0b013e3282f0e3d0, 18090053.
171. Brumme ZL, Dong WW, Yip B, Wynhoven B, Hoffman NG, Swanstrom R, Jensen MA, Mullins JI, Hogg RS, Montaner JS, Harrigan PR. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. Aids 2004, 18:F1-9. 10.1097/00002030-200403050-00001, 15090786.
172. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, Pillai S, Good B, Harrigan PR. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. Aids 2007, 21:F17-24. 10.1097/QAD.0b013e3282ef81ea, 17721088.
173. Low AJ, Marchant D, Brumme CJ, Brumme ZL, Dong W, Sing T, Hogg RS, Montaner JS, Gill V, Cheung PK, Harrigan PR. CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res Hum Retroviruses 2008, 24:219-228. 10.1089/aid.2007.0140, 18240966.
174. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008, 46:1617-1623. 10.1086/587660, 18419499.